Bovine viral diarrhea virus (BVDV) membrane-anchored type I glycoprotein E2 is an ∼53-kDa immunodominant glycoprotein inducing the production of neutralizing antibodies in the animal host after natural infection or following immunization with live or killed vaccines. The E2 coding region lacking the transmembrane domain was constructed in a soluble secreted form (secE2) and expressed in the medium of a transiently transfected human cell line. The crude conditioned medium containing secE2 can be potentially employed to develop an enzyme-linked immunosorbent assay antigen for the diagnosis of BVDV infection or for vaccine purposes. Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Expression of bovine viral diarrhea virus glycoprotein E2 as a soluble secreted form in a mammalian cell line / Donofrio, G.; Bottarelli, E.; Sandro, C.; Flammini, C. F.. - In: CLINICAL AND VACCINE IMMUNOLOGY. - ISSN 1556-6811. - 13:6(2006), pp. 698-701. [10.1128/CVI.00071-06]

Expression of bovine viral diarrhea virus glycoprotein E2 as a soluble secreted form in a mammalian cell line

Donofrio G.
;
Flammini C. F.
2006-01-01

Abstract

Bovine viral diarrhea virus (BVDV) membrane-anchored type I glycoprotein E2 is an ∼53-kDa immunodominant glycoprotein inducing the production of neutralizing antibodies in the animal host after natural infection or following immunization with live or killed vaccines. The E2 coding region lacking the transmembrane domain was constructed in a soluble secreted form (secE2) and expressed in the medium of a transiently transfected human cell line. The crude conditioned medium containing secE2 can be potentially employed to develop an enzyme-linked immunosorbent assay antigen for the diagnosis of BVDV infection or for vaccine purposes. Copyright © 2006, American Society for Microbiology. All Rights Reserved.
2006
Expression of bovine viral diarrhea virus glycoprotein E2 as a soluble secreted form in a mammalian cell line / Donofrio, G.; Bottarelli, E.; Sandro, C.; Flammini, C. F.. - In: CLINICAL AND VACCINE IMMUNOLOGY. - ISSN 1556-6811. - 13:6(2006), pp. 698-701. [10.1128/CVI.00071-06]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2999553
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact